✦ LIBER ✦

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

✍ Scribed by Shahneen K. Sandhu, Kyri Papadopoulos…

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of carlumab (CNTO 888), a

✍ Pienta, Kenneth J.; Machiels, Jean-Pascal; Schrijvers, Dirk; Alekseev, Boris; Sh 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 232 KB

29 A First-in-Human Phase I Monotherapy

✍ Lassen, U.; Schellens, J.H.M.; Siu, L.L.; Jonker, D.J.; Sorensen, M.; Jarutat, T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A phase I study of the human monoclonal

✍ Weekes, Colin D.; Beeram, Muralidhar; Tolcher, Anthony W.; Papadopoulos, Kyriako 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 387 KB

Carlumab, an anti-C-C chemokine ligand 2

✍ Brana, Irene; Calles, Antonio; LoRusso, Patricia M.; Yee, Lorrin K.; Puchalski, 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 370 KB

367 A first-in-human Phase 1 study of an

✍ L. Rosen; M.S. Gordon; H.I. Hurwitz; M.K. Wong; J. Goldman; B.J. Adams; D. Alvar 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

28 A First-in-human Phase I Study to Eva

✍ Smith, D.C.; Chugh, R.; Patnaik, A.; Papadopoulos, K.; Chambers, G.; Thorpe, V.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB